| Main Subject |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Management > Creativity and Innovation Management - Psychological Reward |
|
Main Subject - Creativity and Innovation Management - Psychological Reward
Creativity can be defined as problem identification and idea generation whilst innovation can be defined as idea selection, dev According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product elopment and commercialisation. There are other useful definitions in this field, for example, creativity can be defined as co ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in nsisting of a number of ideas, a number of diverse ideas and a number of novel ideas. There are distinct processes that enhanc lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. e problem identification and idea generation and, similarly, distinct processes that enhance idea selection, development and co here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe mmercialisation. Whilst there is no sure fire route to commercial success, these processes improve the probability that good id d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro eas will be generated and selected and that investment in developing and commercialising those ideas will not be wasted. P ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc sychological Reward Psychological rewards and recognition are major factors in the motivation equation. Status theory a easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi rgues that every action, movement and inflexion of human beings is in some way related to status. There are compelling argument nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically s that human behaviour is based on status seeking. In the animal kingdom, higher status individuals have more sex, more access and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ to food and resources, more space and so forth. The present day occupation with celebrities is a testament to the power of sta ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi tus. Big Brother and reality TV show how far people will go to get it. Status is addressed in the corporate world in expressio ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ns such as “give the dog a bone.” Consequently, there is a tendency to give people high-sounding names without considering the dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod other motivational factors. People either resent this or are happy for only short periods. Psychological rewards include an en cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin vironment of psychological safety and freedom – accepting an individual as unconditioned worth; recognising that the individual tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen is capable of producing but that their value is not based on producing; understanding empathetically; understanding the indivi t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel dual from their point of feeling and view (Vernon, 1970). These and other topics are covered in depth in the MBA dissertation ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust on Managing Creativity & Innovation, which can be purchased (along with an Innovation Management Bible, a Creativity and Innova y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products tion DIY Audit, Good Idea Generator Software and Power Point Presentation) from http://www.managing-creativity.com/ You can al . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de so receive a regular, free newsletter by entering your email address at this site. Kal Bishop, MBA ************************** elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ******** You are free to reproduce this article as long as no changes are made and the author's name and site URL are retained tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:When The Going Gets Tough -- The Tough Keep Going
|